Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
in Jun 16, 2022
Presented at the ASCO annual meeting 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
in Oct 25, 2021
Published in Nature Cancer, October 2021
A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer
in Jun 06, 2021
Presented at ASCO annual meeting 2021
Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2
in Apr 12, 2021
Presented at the AACR annual meeting 2021
NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models
in Apr 01, 2020
Presented at the AACR annual meeting 2020
A phase I/II, Open-label, Dose Escalation Followed by Single-arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with R/M HNSCC
in Feb 01, 2020
Presented at the 2020 multidisciplinary Head and Neck Cancers Symposium
NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2, Combined with Chemotherapy or MEK Inhibitor in Gemcitabine-Resistant Pancreatic Tumors, Induced Tumor Regression
in Apr 01, 2019
Presented at the 2019 AACR Special Conference Pancreatic Cancer
NT219, A Novel Dual Inhibitor of STAT3 and IRS1/2, Converts Immuno-Oncology Resistant Tumors to Responders
in Apr 01, 2018
Presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy
Comprehensive high throughput screen for combination therapies to block acquired resistance to targeted drugs
in Apr 01, 2017
Presented at the AACR annual meeting 2017